Literature DB >> 14656957

Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Aram V Chobanian1, George L Bakris, Henry R Black, William C Cushman, Lee A Green, Joseph L Izzo, Daniel W Jones, Barry J Materson, Suzanne Oparil, Jackson T Wright, Edward J Roccella.   

Abstract

The National High Blood Pressure Education Program presents the complete Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Like its predecessors, the purpose is to provide an evidence-based approach to the prevention and management of hypertension. The key messages of this report are these: in those older than age 50, systolic blood pressure (BP) of greater than 140 mm Hg is a more important cardiovascular disease (CVD) risk factor than diastolic BP; beginning at 115/75 mm Hg, CVD risk doubles for each increment of 20/10 mm Hg; those who are normotensive at 55 years of age will have a 90% lifetime risk of developing hypertension; prehypertensive individuals (systolic BP 120-139 mm Hg or diastolic BP 80-89 mm Hg) require health-promoting lifestyle modifications to prevent the progressive rise in blood pressure and CVD; for uncomplicated hypertension, thiazide diuretic should be used in drug treatment for most, either alone or combined with drugs from other classes; this report delineates specific high-risk conditions that are compelling indications for the use of other antihypertensive drug classes (angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, beta-blockers, calcium channel blockers); two or more antihypertensive medications will be required to achieve goal BP (<140/90 mm Hg, or <130/80 mm Hg) for patients with diabetes and chronic kidney disease; for patients whose BP is more than 20 mm Hg above the systolic BP goal or more than 10 mm Hg above the diastolic BP goal, initiation of therapy using two agents, one of which usually will be a thiazide diuretic, should be considered; regardless of therapy or care, hypertension will be controlled only if patients are motivated to stay on their treatment plan. Positive experiences, trust in the clinician, and empathy improve patient motivation and satisfaction. This report serves as a guide, and the committee continues to recognize that the responsible physician's judgment remains paramount.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14656957     DOI: 10.1161/01.HYP.0000107251.49515.c2

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  2000 in total

1.  Long-term blood pressure fluctuation and cerebrovascular disease in an elderly cohort.

Authors:  Adam M Brickman; Christiane Reitz; José A Luchsinger; Jennifer J Manly; Nicole Schupf; Jordan Muraskin; Charles DeCarli; Truman R Brown; Richard Mayeux
Journal:  Arch Neurol       Date:  2010-05

2.  Epicardial adipose tissue thickness predicts descending thoracic aorta atherosclerosis shown by multidetector computed tomography.

Authors:  Hikmet Yorgun; Uğur Canpolat; Tuncay Hazırolan; Hamza Sunman; Ahmet Hakan Ateş; Kadri Murat Gürses; Ozgür Ertuğrul; Ergün Barış Kaya; Kudret Aytemir; Lale Tokgözoğlu; Giray Kabakçı; Ali Oto
Journal:  Int J Cardiovasc Imaging       Date:  2011-06-03       Impact factor: 2.357

3.  Lower Arterial Cross-Sectional Area of Carotid and Vertebral Arteries and Higher Frequency of Secondary Neck Vessels Are Associated with Multiple Sclerosis.

Authors:  P Belov; D Jakimovski; J Krawiecki; C Magnano; J Hagemeier; L Pelizzari; B Weinstock-Guttman; R Zivadinov
Journal:  AJNR Am J Neuroradiol       Date:  2017-12-07       Impact factor: 3.825

4.  Effect of Intensive Blood Pressure Lowering on Left Ventricular Hypertrophy in Patients With Hypertension: SPRINT (Systolic Blood Pressure Intervention Trial).

Authors:  Elsayed Z Soliman; Walter T Ambrosius; William C Cushman; Zhu-Ming Zhang; Jeffrey T Bates; Javier A Neyra; Thaddeus Y Carson; Leonardo Tamariz; Lama Ghazi; Monique E Cho; Brian P Shapiro; Jiang He; Lawrence J Fine; Cora E Lewis
Journal:  Circulation       Date:  2017-05-16       Impact factor: 29.690

5.  Low-sodium dietary approaches to stop hypertension diet reduces blood pressure, arterial stiffness, and oxidative stress in hypertensive heart failure with preserved ejection fraction.

Authors:  Scott L Hummel; E Mitchell Seymour; Robert D Brook; Theodore J Kolias; Samar S Sheth; Hannah R Rosenblum; Joanna M Wells; Alan B Weder
Journal:  Hypertension       Date:  2012-10-01       Impact factor: 10.190

6.  Roll-in experience from the Cardiovascular Outcomes with Renal Atherosclerotic Lesions (CORAL) study.

Authors:  Timothy P Murphy; Christopher J Cooper; Donald E Cutlip; Alan Matsumoto; Kenneth Jamerson; John Rundback; Kenneth A Rosenfield; William Henrich; Joseph Shapiro; Joseph Massaro; Chen-Hsing Yen; Holly Burtch; Claudia Thum; Diane Reid; Lance Dworkin
Journal:  J Vasc Interv Radiol       Date:  2013-12-08       Impact factor: 3.464

7.  Acceptability of sodium-reduced research diets, including the Dietary Approaches To Stop Hypertension diet, among adults with prehypertension and stage 1 hypertension.

Authors:  Njeri Karanja; Kristie J Lancaster; William M Vollmer; Pao-Hwa Lin; Marlene M Most; Jamy D Ard; Janis F Swain; Frank M Sacks; Eva Obarzanek
Journal:  J Am Diet Assoc       Date:  2007-09

Review 8.  Cardiovascular therapies and associated glucose homeostasis: implications across the dysglycemia continuum.

Authors:  Rhonda M Cooper-DeHoff; Michael A Pacanowski; Carl J Pepine
Journal:  J Am Coll Cardiol       Date:  2009-02-03       Impact factor: 24.094

9.  Videos in clinical medicine. Blood-pressure measurement.

Authors:  Jonathan S Williams; Stacey M Brown; Paul R Conlin
Journal:  N Engl J Med       Date:  2009-01-29       Impact factor: 91.245

10.  Differential expression of vascular smooth muscle-modulating microRNAs in human peripheral blood mononuclear cells: novel targets in essential hypertension.

Authors:  J E Kontaraki; M E Marketou; E A Zacharis; F I Parthenakis; P E Vardas
Journal:  J Hum Hypertens       Date:  2013-11-28       Impact factor: 3.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.